GlassScriptPhysician profile
Flor Geola
NPI 1851485049
$2,981.48
in general payments reported to CMS, 2019-2025
26 companies · $682 in 2025
The $682 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $74.96 · 2021: $371 · 2022: $436 · 2023: $635 · 2024: $502 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,753 · Education: $66.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,752.69 |
| Education | $66.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $573.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $509.60 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Sanofi-Aventis U.S. LLC | $281.30 | 2019-2025 | |
| Amgen INC. | $233.02 | 2019-2025 | Evenity, Prolia, Prolia |
| Abbott Laboratories | $205.83 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.33 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $141.58 | 2021-2025 | |
| Glaxosmithkline, LLC. | $126.01 | 2025 | Nucala |
| Ascendis Pharma Endocrinology INC | $84.25 | 2024-2025 | Yorvipath |
| Horizon Therapeutics Plc | $83.59 | 2021-2023 | Tepezza |
| Merck Sharp & Dohme LLC | $74.78 | 2019-2020 | |
| Mannkind Corporation | $71.12 | 2023-2024 | Afrezza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $66.24 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $64.58 | 2021-2022 | |
| Antares Pharma, INC. | $56.47 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $45.36 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $30.33 | 2025 | Isturisa |
| Radius Health, INC. | $29.44 | 2024 | |
| Beta Bionics, INC. | $26.01 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Xeris Pharmaceuticals, INC. | $23.34 | 2023 | Gvoke Hypopen |
| Ibsa Pharma INC. | $21.54 | 2019 | |
| Pfizer INC. | $18.95 | 2023 | |
| Zealand Pharma US, INC. | $18.01 | 2021 | |
| Shire North American Group INC | $16.37 | 2019 | |
| Azurity Pharmaceuticals, INC. | $15.33 | 2023 | Adthyza |
| Arbor Pharmaceuticals, INC. | $15.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Flor Geola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.